title: An in-silico approach to find a peptidomimetic targeting extracellular domain of HER3 from a HER3 Nanobody.
abstract: HER3 is an important therapeutic target in cancer treatments. HER3 Nanobodies (Nbs) are a novel class of antibodies with several competitive advantages over conventional antibodies. A peptidomimetic derived from these Nbs can be considered to be a small peptide mimicking some of the molecular recognition interactions of a natural peptide or protein in a three-dimensional (3D) space, with a receptor that has improved properties. In this study, we introduce a new approach to design a peptidomimetic derived from HER3 Nb through an in silico analysis. We propose that the complementarity determining region (CDR3) of HER3 Nb is large enough to effectively interact with HER3 antigen as well as with the entire Nb. A computational analysis has been performed using Nb models retrieved from SWISS-pdb Viewer 4.1.0 (spdbv) as a target spot and HER3 extracellular domain as its antigenic target to identify the interactions between them by the protein-protein docking method. Detailed analysis of selected models with docked complex help us to identify the interacting amino acid residues between the two molecules. The results of in silico analysis show that the CDR3 of HER3 Nb might be used by itself as a peptidomimetic drug instead of the full Nb. HER3 peptidomimetic-derived HER3 Nb may reduce Nb production costs and be used as a substitute for HER3 Nb after further experimental work. The paper demonstrates the feasibility of peptidomimetics designs using bioinformatic tools.
authors.affiliation: School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
authors.forename: Z
authors.initials: Z
authors.lastname: Pourhashem
authors.affiliation: School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
authors.forename: M
authors.initials: M
authors.lastname: Mehrpouya
authors.affiliation: Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, Iran; School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran. Electronic address: yardehnavi.najmeh@yahoo.com.
authors.forename: N
authors.initials: N
authors.lastname: Yardehnavi
authors.affiliation: Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
authors.forename: A
authors.initials: A
authors.lastname: Eslamparast
authors.affiliation: Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran.
authors.forename: F
authors.initials: F
authors.lastname: Kazemi-Lomedasht
mesh_terms: D019295:Computational Biology; D003198:Computer Simulation; D006801:Humans; D057786:Peptidomimetics; D000072417:Protein Domains; D020893:Receptor, ErbB-3 / Q000737:chemistry*; D061905:Single-Domain Antibodies / Q000737:chemistry*
chemical_list: D057786:Peptidomimetics; D061905:Single-Domain Antibodies; C581292:ERBB3 protein, human; D020893:Receptor, ErbB-3
keywords: Docking; HER3; Nanobody; Peptidomimetic; in silico